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Abstract
Histone deacetylase inhibitors (HDACIs) are a class of antineoplastic agents previously demonstrating preclinical
chemosensitizing activity against drug-resistant cancer cells and mouse xenografts. However, whereas clinical
studies have shown efficacy against human hematologic malignancies, solid tumor trials have proved disappoint-
ing. We previously developed a novel HDACI, “OSU-HDAC42,” and herein examine its activity against ovarian cancer
cell lines and xenografts. OSU-HDAC42, (i) unlike most HDACIs, elicited a more than five-fold increase in G2-phase
cells, at 2.5 μM, with G2 arrest followed by apoptosis; (ii) at 1.0 μM, completely repressed messenger RNA expres-
sion of the cell cycle progression gene cdc2; (iii) at low doses (0.25-1.0 μM for 24 hours), induced tumor cell epithelial
differentiation, as evidenced by morphology changes and a more than five-fold up-regulation of epithelium-specific
cytokeratins; (iv) potently abrogated the growth of numerous ovarian cancer cells, with IC50 values of 0.5 to 1.0 μM,
whereas also remaining eight-fold less toxic (IC50 of 8.6 μM) to normal ovarian surface epithelial cells; and (v) che-
mosensitizated platinum-resistant mouse xenografts to cisplatin. Compared with the clinically approved HDACI
suberoylanilide hydroxamic acid (vorinostat), 1.0 μM OSU-HDAC42 was more biochemically potent (i.e., enzyme-
inhibitory), as suggested by greater gene up-regulation and acetylation of both histone and nonhistone proteins.
In p53-dysfunctional cells, however, OSU-HDAC42 was two- to eight-fold less inductive of p53-regulated genes,
whereas also having a two-fold higher IC50 than p53-functional cells, demonstrating some interaction with p53
tumor-suppressive cascades. These findings establish OSU-HDAC42 as a promising therapeutic agent for drug-
resistant ovarian cancer and justify its further investigation.
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Introduction
Ovarian cancer is the most lethal gynecological cancer in women.
Whereas stage I disease has a 5-year survival rate of more than 93%,
75% of patients initially present with disseminated (stage III/IV) dis-
ease, for which survival falls to less than 25% [1]. Although surgical
debulking, followed by platinum (e.g., cisplatin or carboplatin) and
taxane regimens, provides responses to more than 70% of patients
[2], more than 85% of those responders eventually relapse, at which
point further therapy options are very limited [2]. Consequently,
strategies aimed at resensitization would greatly reduce the mortality
and human suffering of this devastating malignancy.
In the early 1970s, several compounds were discovered to elicit dif-
ferentiation of Friend erythroleukemia cells; many of these were later
demonstrated to enhance histone acetylation due to the inhibition of
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histone deacetylase (HDAC) enzymes [3,4]. After further in vitro and
animal testing, several of these, and other fortuitously discovered,
compounds (or their derivatives) entered clinical trials [5,6]. These
agents included suberoylanilide hydroxamic acid (SAHA, vorinostat),
depsipeptide (FK228, romidepsin), MS-725 (SNDX-275), and val-
proic acid (VPA, divalproex), and SAHA has now been approved for
cutaneous T-cell lymphoma [7]. Activity against solid tumors, how-
ever, has thus far been disappointing [8–10], and a recent phase 1
ovarian cancer clinical trial of SAHA demonstrated minimal patient
benefit [11]. Whereas some recently examined (third-generation)
HDAC inhibitors have been designed based on now-solved HDAC
structures [12] (with the first structure, that of the HDAC-like pro-
tein, published in 1999) [13], most second-generation compounds
currently in clinical trials (including SAHA, first reported in 1996)
[14] were developed based on their capacity for inducing differenti-
ation of erythroleukemia cells or antitumor activities in mice [14–
17]. Consequently, despite their biological activity, it is possible that
the enzyme-inhibitory activities of those widely studied (and likely
clinically viable) HDACIs could yet be further improved [12].
To address these possibilities, we rationally designed a novel
HDAC inhibitor (HDACI), designated “OSU-HDAC42,” by teth-
ering a short-chain fatty acid to a Zn2+-chelating hydroxamate group,
using a hydrophobic spacer for optimal interaction with the HDAC
active site pocket [18]. Previously, OSU-HDAC42 (NSC-D736012;
AR-42 Arno Therapeutics, Inc., Fairfield, NJ) was found to be more
potent than SAHA against human prostate cancer cells and xeno-
grafts [19], in addition to completely abrogating tumor progression
of a spontaneously occurring mouse model (TRAMP) of that malig-
nancy [20]. In a similar preclinical study of human hepatocellular car-
cinoma, orally administrated OSU-HDAC42 suppressed xenograft
tumor growth by more than 90% (compared with 66% by SAHA),
whereas also being 85% repressive of further growth of preexisting
tumors (i.e., developed before treatment) [21]. Mechanistically,
OSU-HDAC42 was previously demonstrated to disrupt repressive
protein phosphatase 1 interactions with HDACs 1 and 6, allowing
protein phosphatase 1–mediated dephosphorylation (and thus inacti-
vation) of the oncogenic signaling mediator Akt [22]. OSU-HDAC42
was also demonstrated to sensitize drug-resistant DU-145 prostate
cancer cells to double-strand DNA breaking agents by enhancing acety-
lation (resulting in inhibition of DNA binding) of the DNA repair
enzyme Ku70 [23]. Whereas the precise role of Ku70 in the repair of
platinum-DNA adducts (vs double-strand breaks) remains controversial
[24,25], the aforementioned study provided impetus for examining
OSU-HDAC42 as a possible chemosensitizing agent for ovarian can-
cer (a disease that almost inevitably progresses to a platinum-resistant
phenotype) [26].
On the basis of these findings, OSU-HDAC42 has now under-
gone extensive preclinical assessment within the Rapid Access to In-
tervention Development program of the National Cancer Institute,
and was recently licensed to a biopharmaceutical company (Arno
Therapeutics). Similar to most malignancies, advanced-stage ovarian
cancer undergoes a number of epigenetic aberrations, including dys-
regulated HDAC expression [27,28]. In the current preclinical study,
OSU-HDAC42 was found antiproliferative to both ovarian cancer
cells and tumors, based on unique mechanisms of cytostasis, differ-
entiation, and apoptosis, and in combination with cisplatin, OSU-
HDAC42 significantly delayed growth of platinum-resistant tumors
in mice. Whereas most HDACIs elicit cytostasis by G1 arrest [5,29],
OSU-HDAC42 likely elicits G2 blockage through an atypical mech-
anism, that is, transcriptional repression of the cell cycle progression
protein cdc2. In summary, OSU-HDAC42 represents a promising
antineoplastic agent for advanced, drug-resistant ovarian cancer and
warrants further investigation for the therapy for this highly destruc-
tive malignancy.
Materials and Methods
Reagents and HDAC Inhibitor Synthesis
Cisplatin for in vitro study was purchased from Sigma-Aldrich
(St. Louis, MO) and dissolved in PBS at a stock concentration of
2 mM. For in vivo studies, a premanufactured saline solution of cis-
platin (Novaplus, Irving, TX) was used. The HDACIs SAHA and
OSU-HDAC42 were synthesized in our laboratory [18]. For in vitro
studies, stock solutions were prepared in DMSO and diluted in cul-
ture medium for cell treatments. For in vivo studies, HDACIs were
prepared as suspensions in vehicle (0.5% methylcellulose, 0.1%
Tween 80, in sterile water). Antibodies against PI3K, PTEN, Akt,
acetyl-H3, phospho-Ser473-Akt, and cdc2 were purchased from Cell
Signaling Technology (Danvers, MA), anti–histone H3 from Upstate
(Lake Placid, NY), and antibodies against p21 and cyclin B1 from
Santa Cruz Biotechnology (Santa Cruz, CA). Cell culture reagents
were from Invitrogen (Carlsbad, CA) or HyClone (Logan, UT).
Cell Culture Studies
The p53+/+ cisplatin-sensitive human ovarian cancer cell line A2780
was purchased from the European Collection Association of Cell
Culture (Cambridge, United Kingdom), whereas the cisplatin-resistant
cell lines CP70 (p53-mutant) and OVCAR10 (p53-functional) were
kindly provided by Dr. T-H.M. Huang (Ohio State University).
A2780, CP70, and OVCAR10 cells were cultured at 37°C, under
5% CO2, in RPMI-1640 medium supplemented with 10% FBS
and 2 mM L-glutamine. Primary normal ovarian surface epithelial
(NOSE) cells were obtained from healthy women by gentle brushing
of the ovarian surface, followed by short-term (two to four passages)
expansion in culture, as previously described [30].
Dose-Response Studies of Normal Epithelial or Malignant
Ovarian Cells
To assess cell viability, cells (5000/well in 96-well plates) were treated
with various concentrations of OSU-HDAC42 (see figures), for 2 days,
followed by analysis of MTT (TCI America, Portland, OR) tetra-
zolium salt metabolism [19], using six experimental replicates. That
specific starting cell number (5000/well) was selected for the 48-hour
incubation based on the assumption of subconfluency after three cell
divisions or less (and thus approximately 40,000 cells/well), with
50,000 cells representing a confluent well of 0.3-cm2 surface area
(http://www.bdbiosciences.com). For NOSE cells (see previous para-
graph), which divide substantially more slowly than transformed cells
[31], 10,000 cells were seeded per well, with 5-day drug treatments.
On the basis of the resultant A570 readings, IC50 values (i.e., drug
dose requirements for 50% growth inhibition) were determined by
Calcusyn (Biosoft, Cambridge, UK), using the “median-effect” meth-
od [32], or Prism 4, using sigmoidal dose (variable slope) curve fit-
ting (GraphPad Software, San Diego, CA).
Western Blot Analysis
For immunoblot analysis, OSU-HDAC42–treated (48 hours, see
figures) cells were lysed followed by protein isolation and quantification
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(Bradford assay; Bio-Rad, Hercules, CA) and SDS-PAGE. Proteins
were then transferred to nitrocellulose membranes and subjected to
immunoblot analysis as previously described [19].
Semiquantitative or Fully Quantitative Reverse
Transcription–Polymerase Chain Reaction Assessments
of Gene Expression
For gene expression analysis, OSU-HDAC42–treated cells (see fig-
ures) were harvested, total RNA–extracted (RNeasy; Qiagen, Valencia,
CA), reverse-transcribed using an iScript cDNA synthesis kit (Bio-
Rad). After reverse transcription, cDNAwas polymerase chain reaction
(PCR)–amplified for specific gene transcripts, for 30 cycles, and ana-
lyzed on 2% agarose (semiquantitative analysis) or was mixed with
a SYBR green–based PCR reaction mixture (Roche Applied Science,
Indianapolis, IN) and analyzed for 45 cycles (fully quantitative anal-
ysis) using a LightCycler 2.0 real-time PCR instrument (Roche). Rel-
ative changes in transcript levels were determined by the 2(−ΔΔCt)
method [33] using β-actin or E2F-1 as reference housekeeping genes.
Gene-specific primer sequences are available upon request.
Cell Cycle Distribution Analyses
After various 48-hour drug treatments (see figures), cells (1 × 106)
were harvested, and processed as previously described [21], with flow
cytometry performed using a FACSCalibur (BD Biosciences, Franklin
Lakes, NJ) instrument and data analysis using ModFit (Verity Soft-
ware House, Topsham, ME). For sub-G1 population analysis, both
floating and adherent cells were collected.
Annexin V/Propidium Iodide Apoptosis Analysis
To quantify apoptosis, cells (2 × 105 per well in six-well plates)
were treated for 48 hours with media or 0.5, 1.0, or 2.5 μM
OSU-HDAC42. After drug treatments, both floating and adher-
ent cells were collected, stained with a propidium iodide (PI)/annexin
V–fluorescein solution (Invitrogen) for 15 minutes at room temper-
ature in the dark, and flow cytometry was performed as described
previously. For drug combination studies, cells were pretreated for
4 hours with OSU-HDAC42 (see text for doses) followed by media
or 5, 10, or 25 μM cisplatin for 48 hours.
Cell Morphology and Cytokeratin Expression Analyses
To examine drug-induced ovarian cancer cell morphology changes,
cells (2 × 105 per well in six-well plates) were treated for 24 hours
with 0 to 2.5 μM OSU-HDAC42, followed by photography under
phase-contrast magnification. For the assessment of epithelial dif-
ferentiation, CP70 cells were grown on coverslips, treated with ve-
hicle, 0.5, or 1.0 μM OSU-HDAC42 for 48 hours, and fixed with
4% paraformaldehyde for 20 minutes at 37°C. Fixed cells were then
washed with PBS, blocked for 1 hour in PBS containing 1% FBS and
0.1% Triton X-100, and incubated with the monoclonal antibody
(1:100 in PBS/0.1% BSA) cocktail AE1/AE3 (DakoCytomation,
Carpinteria, CA), which recognizes most human cytokeratins [34],
for 24 hours. Cells were then washed thrice with PBS, incubated
with 3% H2O2 (in PBS) for 5 minutes to inactivate endogenous
peroxidases, washed twice, and incubated with biotin-conjugated
anti–mouse antibodies, followed by streptavidin-peroxidase. Finally,
pan-cytokeratins were detected using a diaminobenzidine substrate
kit (Vector Labs, Burlingame, CA).
For quantifying OSU-HDAC42–mediated CP70 epithelial differ-
entiation, we performed flow cytometry again using AE1/AE3. Briefly,
48 hours OSU-HDAC42–treated cells were washed, fixed in 50%
ethanol overnight (at −20°C), pelleted, PBS-washed, and permeabil-
ized with PBS/0.1% Triton X-100 for 10 minutes at room temper-
ature. After washing, cells were resuspended in 100 μl AE1/AE3
(1:100 in PBS/0.1% BSA) for 2 hours at room temperature on a
rocker. After PBS washing of primary antibody, cells were stained
(in the dark) with 100 μl of Alexa Fluor 488 goat anti–mouse
IgG (Invitrogen; 1:200 in PBS/0.1% BSA) on a rocking platform
for 2 hours at room temperature. Five hundred milliliters of PBS
was then added to increase the volume for flow cytometric analysis
(described previously).
In Vivo Xenograft Drug Sensitivity Tumor Studies
Mouse xenograft studies were carried out with strict adherence to
protocols approved by the Institutional Animal Care and Use Com-
mittee of The Ohio State University. Female athymic nude mice
(NCr-nu/nu, 5-7 weeks of age), obtained from the National Cancer
Institute (Frederick, MD), were subcutaneously inoculated with 5 ×
105 CP70 cells, in 0.1 ml of Matrigel (BD Biosciences; 50% [v/v] in
serum-free medium), in the right dorsal flank. When individual tu-
mors reached a volume of 100 mm3, mice were randomized into
eight groups (eight mice/group) for treatment with the following:
1) vehicle; 2) 6 mg/kg cisplatin every 6 days; 3) 25 mg/kg OSU-
HDAC42 once daily; 4) 50 mg/kg OSU-HDAC42 every other
day; 5) 50 mg/kg SAHA once daily; 6) 25 mg/kg OSU-HDAC42
once daily and 6 mg/kg cisplatin every 6 days; 7) 50 mg/kg OSU-
HDAC42 every other day with 6 mg/kg cisplatin; and 8) 50 mg/kg
SAHA once daily with 6 mg/kg cisplatin (Table W1). Vehicles used
for in vivo studies were PBS (cisplatin) and 0.5% methylcellulose,
0.1% Tween 80, in sterile water (for HDACIs). Histone deacetylase
inhibitor doses were based on an in vivo mouse SAHA study of pros-
tate cancer xenografts [35], whereas the cisplatin dose was based
on a previous ovarian cancer xenograft study [36]. Vehicle, OSU-
HDAC42, and SAHA were each administered by oral gavage, and
cisplatin was administered by intraperitoneal injection. Tumor sizes
were measured weekly using calipers and volumes calculated using
the standard formula: width2 × length × 0.52. Tumor growth times
were assessed by Kaplan-Meier analysis [37], with survival defined as
the period from the onset of treatment to a tumor size of 2000 mm3
(the point of animal sacrifice, in accordance with our animal use pro-
tocol). Log-rank tests were used for statistical comparisons.
Results
OSU-HDAC42 Exhibits Antigrowth Activity against Ovarian
Cancer, But Not Normal, Epithelial Cells
To examine the antiproliferative activity of OSU-HDAC42 against
ovarian cancer, three cell lines were used: 1) A2780 (cisplatin-sensitive);
2) CP70, a platinum-resistant A2780 subline generated by cisplatin
selection (i.e., having “acquired resistance”) [38]; and 3) OVCAR10,
a cisplatin-resistant line that originated from a relapsed ovarian
cancer patient (i.e., “intrinsically resistant”) [39]. In comparable
agreement with previous studies (which used 72-hour rather than
48-hour cisplatin exposure) [38,40], A2780 cells demonstrated a
high sensitivity to cisplatin (IC50 value of 3.2 μM), after 48 hours
of treatment, whereas CP70 and OVCAR10 were 13- to 17-fold
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more resistant, with IC50 values of 42.6 and 53.1 μM, respectively
(Figure W1). Consequently, these three cell lines could be sug-
gested to mimic early-stage responsive (A2780 cells), never-responsive
(OVCAR10 cells), and relapsed (CP70 cells) ovarian cancer patients
[38,39]. However, despite these differing platinum responses, all three
cell lines demonstrated low-dose sensitivities to a 48-hour OSU-
HDAC42 treatment, with IC50 values of 0.6 μM for A2780 cells,
1.1 μM for CP70 cells, and 1.1 μM for OVCAR10 cells (Figure 1A),
Figure 1. OSU-HDAC42–mediated growth inhibition, histone acetylation, cell cycle protein regulation, and cell cycle arrest in ovarian
cancer and normal epithelial cell lines. (A) OSU-HDAC42 dose-responsive growth inhibition in cisplatin-sensitive A2780 (p53+/+; gray
boxes) and cisplatin-resistant CP70 (p53-dysfunctional; black triangles) and OVCAR10 (p53+/+; inverted triangles) ovarian cancer cell
lines (48-hour treatments) compared with NOSE (gray triangles) primary cells (5-day treatments). Means ± SE. (B) Forty-eight–hour dose-
dependent OSU-HDAC42–induced acetylation of histone H3 and regulation of cell cycle–inhibitory (p21) and cell cycle–progression (cy-
clin B1 and cdc2) proteins (loading control, β-actin). (C) A direct comparison of CP70 cell histone H3 acetylation after OSU-HDAC42
versus SAHA treatment (both at 1.0 μM for 1-12 hours). (D) Reverse transcription–PCR analysis of OSU-HDAC42 transcriptional regula-
tion of the cyclin-dependent kinase-encoding gene cdc2 in CP70 cells.
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indicating potent cytoxicity of this compound regardless of cisplatin-
resistant phenotype. In a similar, direct comparison, growth-inhibition
studies (72-hour treatments) of three ovarian cancer cell lines, OSU-
HDAC42 IC50 doses were found to be comparable to or less than
those for SAHA (Table W2).
As a control for toxicity, we examined the effects of OSU-
HDAC42 on primary NOSE cells [31]. Owing to the slower growth
of NOSE cells [30,31], drug treatments were extended to 5 days to
allow for a similar number of cell divisions. As shown in Figure 1A,
OSU-HDAC42 was more than eight-fold less toxic to NOSE cells
(IC50 of 8.9 μM) than to A2780, CP70, or OVCAR10 cells, dem-
onstrating this agent to be antiproliferative to ovarian tumor cells at
doses nontoxic to the normal epithelium from which they derive.
OSU-HDAC42 Induces G2/M Cell Cycle Arrest by Uniquely
Altering Expression of the Cell Cycle Regulators p21, cdc2,
and cyclin B1
As the characteristic effects of known HDACIs include acetylation
of both histone and nonhistone proteins, up- or down-regulation
of specific gene products, and cell cycle arrest [10], we examined
OSU-HDAC42 for these (or its own unique) mechanistic activities.
Analogous to previously characterized HDACIs [5,6], the 48-hour
treatment with OSU-HDAC42 substantially enhanced acetylation
of bulk histone H3 in all three cell lines (Figure 1B); additionally,
acetylation was more pronounced, at 1 μM, than the identical treat-
ment with SAHA (Figure 1C ). In addition, the expression of the
cell cycle inhibitor p21 was elevated by OSU-HDAC42, whereas
the G2/M cell cycle progression proteins cdc2 and cyclin B1 were
downregulated (Figure 1B) [41]; moreover, semiquantitative reverse
transcription–PCR revealed cdc2 down-regulation to occur at the
messenger RNA (mRNA) level (Figure 1D).
As dysregulation of cell cycle regulatory proteins suggests an al-
tered cell cycle distribution, we performed flow cytometry to quan-
titate DNA content after OSU-HDAC42 treatment by PI DNA
staining. As shown in Table 1, G2/M fractions of A2780 and CP70
were substantially (more than five-fold) elevated in a dose-dependent
manner, with only a two-fold increase in the OVCAR10 G2/M index.
In CP70 and A2780 cells, the G1 fraction demonstrated a slight
but definite decrease at the higher (2.5 and 5.0 μM) doses, whereas
no G1 change was observed in OVCAR10 cells. Thus, in accord with
the protein expression results (Figure 1B), OSU-HDAC42–mediated
G2/M cell cycle arrest roughly correlated with p21 up-regulation and
down-regulation of both cdc2 and cyclin B1.
To further examine the transcriptional regulation of cell cycle pro-
teins and a possible role for the p53 tumor suppressor in OSU-
HDAC42–treated ovarian cancer cells, we performed quantitative
reverse transcription–PCR analysis of the p53-dependent, proapop-
totic gene NOXA [42], the partially p53-regulated gene p21 (p21 is
also directly induced by histone hyperacetylation) [6], and two p53-
independent genes, Apaf-1 and γ-globin, in A2780 (p53-positive)
and CP70 (p53-null) cells treated with 1 μM drug for 24 hours.
As shown in Figure W2, both OSU-HDAC42 and SAHA induced
NOXA in A2780 cells (A) but not in CP70 cells (B). Similarly, OSU-
HDAC42 induced p21 by 7- and 4.5-fold in A2780 and CP70 cells,
respectively, with corresponding SAHA-induced increases of 5.3- and
2.4-fold. Whereas that result differed somewhat from the p21 West-
ern blot (Figure 1B), it is difficult to presume that protein levels
(based on stability for 48 hours) would mimic mRNA induction
(during a 24-hour period). In contrast, the two p53-independent
genes, Apaf-1 and γ-globin, were not differentially upregulated by
either HDACI in A2780 versus CP70 cells. These findings, in addi-
tion to the higher IC50 for OSU-HDAC42 in CP70 cells (Figure 1A),
suggest that OSU-HDAC42, at least in part, interacts with the p53
tumor suppressor pathway.
Dose-Dependent Acetylation of α-Tubulin and Induction of
Apoptosis by OSU-HDAC42
As mentioned in a previous paragraph, it is now well established
that numerous nonhistone proteins are also HDAC substrates [6,43].
Because α-tubulin is often hyperacetylated after HDACI treatment
[44], we examined the acetylation status of this microtubule-associated
protein in HDACI-treated cells. As shown in Figure 2A, α-tubulin
was highly acetylated, even at low (0.25 μM) OSU-HDAC42 doses,
in both A2780 (left panel ) and CP70 (right panel ) cells. Moreover, in
CP70 cells, α-tubulin acetylation was more pronounced after 1 μM
OSU-HDAC42 treatment than with 1 μM SAHA (Figure 2B). Be-
cause those two agents possess fairly similar structures (according to
Lipinsky’s rules of drug-like properties) [45], their cellular uptake (i.e.,
membrane permeability) would likely be comparable. Consequently,
these tubulin deacetylase inhibition results might suggest a greater
biochemical potency for OSU-HDAC42 compared with SAHA.
Because α-tubulin acetylation by HDACIs has previously been
associated with apoptosis [44], we investigated the effects of OSU-
HDAC42 on cell death by three independent assessments: 1) PI
stain–based sub-G1 cell fraction analysis (i.e., detection of cells with
fragmented DNA), 2) apoptotic cleavage of the DNA repair enzyme
poly(ADP) ribosylase polymerase (PARP), and 3) annexin V–FITC
staining of externalized plasma membrane phosphatidylserine, in
conjunction with PI DNA staining of nonviable cells. As shown
in Figure 3A, OSU-HDAC42 dose-dependently (0-2.5 μM) induced
sub-G1 cell accumulation in all three cell lines tested. Similarly, PARP
cleavage (Figure 3B) and annexin V/PI staining (Figure 3C ) dem-
onstrated similar OSU-HDAC42 dose dependencies. Thus, in agree-
ment with the results of our cell cycle analyses (Table 1), the CP70 and
A2780 ovarian cancer cell lines showed relatively low-dose (approxi-
mately 1 μM) susceptibilities to OSU-HDAC42–induced apoptosis,
whereas OVCAR10 cells required a greater dose (2.5 μM) for substan-
tial apoptosis.
OSU-HDAC42–Induced Cell Morphology Changes and
Epithelial Differentiation
To evaluate possible effects of OSU-HDAC42 on cancer cell dif-
ferentiation, as reported for other HDACIs [46,47], we examined
Table 1. Dose-Dependent Effects of OSU-HDAC42 on Cell Cycle Distributions in A2780,
CP70, and OVCAR10 Cells.
[OSU-HDAC42] (μM) 0 0.25 0.5 1.0 2.5 5.0
A2780 G1 (%) 49 56 58 56 46 43
S (%) 41 29 19 13 8 8
G2/M (%) 9 15 22 31 46 49
CP70 G1 (%) 55 47 53 60 41 31
S (%) 35 39 30 13 10 12
G2/M (%) 10 14 17 27 50 56
OVCAR10 G1 (%) 60 63 69 72 67 68
S (%) 28 24 20 4 5 4
G2/M (%) 12 13 11 24 29 28
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changes in ovarian cancer cell morphology and cytokeratin expression
after OSU-HDAC42 treatment. As shown in Figure 4A, the 24-hour
OSU-HDAC42 treatment resulted in dose-dependent, progressive
morphological changes from round to flat/elongated in both cisplatin-
sensitive (A2780; upper panel ) and -resistant (CP70; lower panel ) cells.
These changes in cell morphology were also associated with increases
in cytokeratin expression as determined by immunocytochemistry.
As shown in Figure 4B, the 48-hour OSU-HDAC42 treatment of
A2780 and CP70 cells resulted in diaminobenzidine staining (brown
stain) of the pan-cytokeratin monoclonal antibody cocktail AE1/AE3
[34], demonstrating up-regulation of these epithelium-specific markers.
To quantitate cytokeratin expression, flow cytometric assessment re-
vealed dose-dependent increases in AE1/AE3 binding (Figure 4B, inset
numbers) in both cell lines after the 48-hour OSU-HDAC42 treatment.
Together, these results support the induction of epithelial differentiation
in ovarian cancer cells after treatment with OSU-HDAC42.
OSU-HDAC42 Sensitizes Platinum-Resistant CP70 Cells to
Cisplatin-Induced Apoptosis
In a previous study, OSU-HDAC42 was demonstrated to resensi-
tize chemoresistant DU-145 prostate cancer cells to various agents
that induce double-strand DNA breakage by acetylation of the
DNA repair enzyme Ku70 [23]. Although the role of Ku70 in re-
sponse to platinum drugs (routinely used against advanced ovarian
cancer and which induce the formation of bulky DNA adducts rather
than double strand breaks) [48] is fairly controversial [24,25], we
examined whether OSU-HDAC42 could similarly elicit chemosensi-
tization to these commonly used chemotherapeutics. Additional ra-
tionale for the assessment of OSU-HDAC42 cisplatin sensitization
was based on the evidence of OSU-HDAC42–induced epithelial
differentiation in the cisplatin-resistant cell line CP70 (described pre-
viously mentioned) and recent hypotheses implicating poorly differ-
entiated tumor progenitors in drug resistance [49]. CP70 cells were
pretreated with OSU-HDAC42 for 4 hours at 1.0 μM (the IC50
value for CP70; Figure 1A) followed by treatment with increasing
concentrations of cisplatin for 2 days and assessment of cell viability
by MTT assay. As shown in Figure 5A, HDACI pretreatment sub-
stantially increased the sensitivity of CP70 cells to cisplatin, lowering
its IC50 value more than 30-fold (analysis not shown). Similar drug
response analyses (Figure W3) revealed no OSU-HDAC42 enhance-
ment of cisplatin’s effects on the already-sensitive A2780 cells (A),
whereas highly chemoresistant OVCAR10 cells demonstrated in-
creased cisplatin sensitivity, similar to that observed in CP70 cells,
after 1.0 μM (the OVCAR10 IC50 dose) HDACI pretreatment
(B). To assess whether this loss of CP70 cell number (as shown by
MTT assays), after the combination treatment, was due to apopto-
sis, cisplatin-induced PARP cleavage was examined with or without
OSU-HDAC42 pretreatment. As shown in Figure 5B, the OSU-
HDAC42/cisplatin combination caused a marked enhancement of
PARP cleavage at 25 μM cisplatin indicating induction of apoptosis.
Similar to the PARP analysis, a second assessment of apoptosis in
CP70 cells using annexin V/FITC flow cytometric analysis (Fig-
ure 5C ) indicated that whereas OSU-HDAC42 alone induced apop-
tosis (23% FITC-positive cells), an enhanced effect (in combination
with 1.0 μM OSU-HDAC42) was observed at 25 μM cisplatin
(38% annexin-labeled cells) compared with cisplatin alone (5% annexin-
labeled cells). Analysis of those OSU-HDAC42/cisplatin combina-
tions revealed an additive but not synergistic effect of the HDAC
inhibitor on cisplatin sensitivity (analysis not shown).
Also in agreement with MTT assays, OSU-HDAC42 pretreatment
of chemosensitive A2780 cells resulted in no apparent increase in
PARP cleavage in cisplatin-treated cells (Figures W3 and W4A). How-
ever, the annexin V/FITC analyses of that cell line was somewhat
contradictory to the other two cell viability assessments, with A2780
showing additive OSU-HDAC42/cisplatin effects (Figure W4B). On
the basis of the presence of both PI and annexin V staining (upper right
quadrants; double-positive cells), it is possible that these cells under-
went necrosis as well as apoptosis [50].
In Vivo Antitumor Platinum Sensitization of
Cisplatin-Resistant CP70 Xenograft Tumors
On the basis of its chemosensitizing and differentiating effects
(Figures 4 and 5), we evaluated the effects of OSU-HDAC42 on
the growth of CP70 xenograft tumors, alone or in combination with
cisplatin, in immunodeficient (NCr-nu/nu) nude mice. After sub-
cutaneous injection of 5 × 105 CP70 cells, mice bearing established
tumors (100 mm3) were randomized to eight distinct treatment
groups (see Materials and Methods and Table W1), with doses based
Figure 2. OSU-HDAC42–induced acetylation of histone H3 and α-tubulin, in comparison to the HDAC inhibitor SAHA. (A) OSU-HDAC42
dose-dependent α-tubulin acetylation in A2780 (left panel) and CP70 (right panel) cells. (B) A direct comparison of SAHA- versus OSU-
HDAC42–mediated tubulin acetylation after 1 μM drug treatment for 6 or 24 hours.
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on similar HDACI and cisplatin mouse xenograft studies [35,36].
Tumor growth was assessed by Kaplan-Meier analysis [37], with sur-
vival duration defined as the time for tumors to reach a volume of
2000 mm3. As shown in Figure 6A, the combination treatment of
OSU-HDAC42, at 50 mg/kg, with cisplatin (purple line) significantly
prolonged survival, that is, delayed tumor growth (P = .0021, log-
rank test) compared with vehicle control (blue line). In contrast, daily
treatment with SAHA, both singly, at 50 and 25 mg/kg (data not
shown), and in combination with cisplatin, did not significantly in-
hibit tumor growth in this model (Figure 6B). These data suggest
that OSU-HDAC42 can resensitize platinum-resistant ovarian tumors
to cisplatin in vivo.
Figure 3. Further examination of apoptotic events induced dose-dependently by a 48-hour OSU-HDAC42 treatment of A2780, CP70, and
OVCAR10 cells, including (A) a 48-hour OSU-HDAC42 dose-dependent accumulation of sub-G1 (i.e., sub-2N) DNA (representing apopto-
tic cellular debris) after treatment of A2780, CP70, and OVCAR10 cells, as assessed by flow cytometric analysis of PI-stained, fixed, and
permabilized cells. (B) Poly(ADP-ribose) polymerase cleavage by caspase 3. (C) Annexin V–FITC binding to membrane-exposed phos-
phatidylserine concomitant with PI viability staining.
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Discussion
Intracellular protein acetylation is intimately involved in numer-
ous biological processes, including cell growth, intracellular signaling,
and gene regulation [43], and a disrupted “acetylome” (i.e., the total
acetylation state of a cell) is well associated with neoplasia [6]. His-
tone deacetylase inhibitors (HDACIs) are a family of compounds
originally discovered as inducers of erythroleukemia cell differentia-
tion [3]; these differentiating agents were only later discovered to
increase histone acetylation through the inhibition of deacetylase en-
zymes [4]. In preclinical studies of ovarian cancer, a number of
HDACIs have demonstrated impressive antiproliferative (and gener-
ally nontoxic) effects against cultured cells and xenograft tumors. In
one study, the long-standing anticonvulsant, VPA (Depakote), im-
pressively (∼80%) suppressed the growth of xenograft tumors of the
ovarian cancer cell line SKOV3, with significant p21 up-regulation
in tumor tissues [51]. Despite encouraging preclinical studies, how-
ever, VPA has proved fairly disappointing in clinical trials for myeloid
malignancies [52], diminishing optimism for its eventual use against
human solid tumors. Another rationally designed hydroxamic acid
HDACI, PXD-101 (belinostat), has demonstrated impressive anti-
tumor effects against aggressive ovarian cancer xenografts [53,54]
and is now in clinical trials. Overall, however, in contrast to hemato-
logic malignancies, single-agent trials of HDACIs for solid tumors, in-
cluding ovarian cancer, have only rarely demonstrated measurable
patient responses [8,9,11].
Whereas HDACIs may lack efficacy as monotherapies, it is gener-
ally agreed that these agents will be most effective in combination
with other agents [5,9]. In a preclinical study similar to our current
work, VPA was found to resensitize CP70 and other resistant ovarian
cancer cell lines to cisplatin, although the cisplatin IC50 values re-
ported in that study (A2780, 0.25 μM; CP70, 5.0 μM, using a
shorter 24-hour treatment) [55] were much lower than those we
observed (A2780, 3.2 μM; CP70, 42.6 μM, 48-hour treatment;
Figure W1). Consequently, because single-agent cisplatin was found
to be much more cytotoxic than in our study, the actual resensitiza-
tion by VPA pretreatment (in that work) was greatly diminished
compared with the OSU-HDAC42–mediated resensitization that
we report here (Figure 5). In other preclinical studies, the benzamide
HDACI M344 was found to inhibit the growth of SKOV3 ovarian
cancer cells with an IC50 of 5.1 μM [56], a lower potency than OSU-
HDAC42 against similarly aggressive malignant cell lines (Figure 1A).
Another hydroxamate HDACI, trichostatin A (TSA), was found to
activate the oncogenic EGFR/Akt signaling pathway in CAOV3
ovarian cancer cells [57], a finding that is in direct contrast to OSU-
HDAC42, which induces the dephosphorylation and inactivation of
Akt [22]. In another study, however, TSA was found to enhance the
sensitivity of ovarian cancer cells to various DNA-damaging agents
[58], an activity also attributed to OSU-HDAC42, which sensitizes
prostate cancer cells to agents that induce DNA double-strand breaks
through the hyperacetylation (and subsequent suppression of DNA-
binding activity) of the DNA repair protein Ku70 [23].
Mechanistically, it seems that the effects of OSU-HDAC42 are
distinct from most previously studied hydroxamic acid HDACIs.
Whereas most HDACIs exert G1 arrest [5,29] or abrogate a G2
checkpoint [59], OSU-HDAC42 was found to cause G2-phase cell
accumulation and, interestingly, a distinct G1 fraction decrease in
cisplatin-resistant CP70 cells (Table 1). Moreover, this G2 arrest may
occur through an unconventional mechanism. Whereas OSU-HDAC42
Figure 4. OSU-HDAC42–induced epithelial differentiation of ovarian cancer cells. (A) Dose-dependent morphologic changes after a 24-hour
OSU-HDAC42 treatment of A2780 (upper panel) and CP70 (lower panel) cells. (B) Up-regulation of numerous cytokeratins (as assessed by
AE1/AE3 monoclonal antibody cocktail staining) in A2780 (upper panel) and CP70 (lower panel) cells after a 48-hour OSU-HDAC42 treat-
ment. Inset numbers: flow cytometric quantification of AE1/AE3–positive CP70 cells.
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Figure 5. OSU-HDAC42–mediated chemosensitization and apoptosis of platinum-resistant CP70 ovarian cancer cells to cisplatin. Cells were
pretreated for 4 hours with 1.0 μM OSU-HDAC42 (CP70 IC50 dose) followed by a 48-hour treatment with media or 1, 5, 10, 25, or 50 μM
cisplatin. Cisplatin sensitivities were then assessed by (A) MTT cell viability assay, (B) PARP cleavage by caspase 3, and (C) annexin V fluo-
rescent staining of externalized phosphatidylserine (an early apoptotic event) coupled with PI staining for loss of membrane integrity.
Figure 6. Kaplan-Meier survival analysis of CP70 tumor-bearing athymic nude mice treated with OSU-HDAC42 (A) or SAHA (B) alone or in
combination with cisplatin. Survival was based on the length of time after CP70 cell subcutaneous engraftment for a specific animal’s
tumor to reach a volume of 2000 mm3 (time of animal sacrifice). See Materials and Methods and Table W1 for a description of mouse
treatment groups (eight randomized mice per group). As shown, only the OSU-HDAC42/cisplatin combination treatment group demon-
strated prolonged survival (P = .0021).
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elicited down-regulation of cyclin B1 (Figure 1B), an event previ-
ously associated with other HDACIs [5,60], we also observed a
likely transcriptional repression (although we cannot rule out
mRNA degradation) of the cyclin-dependent kinase-encoding gene
cdc2, which, to our knowledge, is a previously unreported HDACI-
associated phenomenon. Although the mechanism of cdc2 tran-
scriptional repression remains uncertain, it has been reported that
HDACIs can restore p53 function to cells harboring mutations in
that specific tumor suppressor [61] and also that p53 interference
with NF-Y–mediated transactivation can downregulate cdc2 [62].
Moreover, the p53 transcription factor itself is acetylated (and thus
activated) through HDACI inhibition of HDAC6 [5,9]. Another
possible mechanism for cdc2 silencing could be through OSU-
HDAC42 up-regulation of the expression and/or activity of the cell
cycle–dependent element–binding factor 1, a repressor of cdc2 and
other growth-promoting genes [63]. Interestingly, HDACIs have
also been demonstrated to downregulate specific genes (including
cyclin B1) [60] by histone deacetylation, possibly due to the induc-
tion of NADH-dependent class III HDACs, which are not inhib-
ited by zinc-chelating hydroxamic acid HDACIs [64].
Although not a clinically viable HDACI [5], contrasting the effects
of TSA with those of OSU-HDAC42 may prove informative regard-
ing the antitumor mechanism(s) of the latter compound. As shown
in Table 1, OSU-HDAC42 was found to induce prominent G2 arrest
in both cisplatin-resistant (CP70) and -sensitive (A2780) cells, with a
lesser G2 effect noted in OVCAR10 cells. A smaller-magnitude G1
arrest was also observed in the former two cell lines; however, the G1
fraction was relatively unchanged in OVCAR10 cells, which also pos-
sessed a much lower S-phase index, in agreement with a previous re-
port comparing the relative radiosensitivity of these various ovarian
cancer cells [65]. Trichostatin A, by contrast, was previously found to
shift its mode of cell cycle arrest from G1 to G2 upon the acquisition
of cisplatin resistance (i.e., elicit G1 blockage in A2780 cells, with
G2 accumulation of CP70 cells) [47]. Also, in contrast to OSU-
HDAC42, TSA was demonstrated to bypass mitochondrial apoptosis
in CP70 cells, through the up-regulation of p73 and Bax [66]. Al-
though we did not examine intrinsic versus extrinsic apoptosis in
this work, other studies demonstrating that OSU-HDAC42 elicits
cytochrome C cytosolic accumulation [19] and down-regulation of
Bcl-xL [21], suggest (at least partial) induction of cell death by
mitochondria-associated cascades. Thus, OSU-HDAC42 exerts its
antineoplastic activity much differently than TSA, despite the two
agents having similar zinc-chelating (hydroxamate) moieties.
One topic of current debate is whether isoform-specific or pan-
HDAC inhibitors will be most effective as antitumor agents [9,10].
Although no assessments of the effect of OSU-HDAC42 on specific
HDAC isoforms have been performed, based on studies to date
[19,21–23], it is fairly certain that OSU-HDAC42 is a pan-HDAC
inhibitor as demonstrated by its inhibition of both class I (histone-
deacetylating) and class II (including HDAC6, the deacetylase of
tubulin) [67] enzymes. Whereas the issue of the clinical superiority
of pan- versus isoform-specific HDAC inhibitors remains an open
question, acetylation of tubulin, previously correlated with HDACI-
induced apoptosis [44], may be indispensable to the antitumor ac-
tivity of OSU-HDAC42. Moreover, it has recently been demonstrated
that HDAC6 is essential for apoptosis resistance and tumor growth
of SKOV3 ovarian cancer xenografts [68], thus supporting inhibition
of that particular class II deacetylase (HDAC6), as well as class I en-
zymes, as necessary prerequisites for the therapy for ovarian cancer.
In summary, we demonstrate that the novel HDAC inhibitor
OSU-HDAC42 is highly growth-suppressive of ovarian cancer cells
and tumors and acts (at least in part) through unconventional mech-
anisms, with similar or greater potency than previously established
hydroxamate HDACIs. Consistent with a previous mechanistic study
[23], we found that OSU-HDAC42/cisplatin combinations effec-
tively resensitize cisplatin-resistant malignant cells and delay cisplatin-
resistant tumor growth in xenograft tumors in vivo. Overall, these
results strongly indicate OSU-HDAC42 to be a promising candidate
for the treatment of drug-resistant ovarian cancer, a disease in dire need
of improved interventional approaches.
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Table W1. Randomization of Mice into Eight Separate Treatment Groups (n = 8 per Group) after Tumor Development to 100 mm3.
Treatment Group Intervention No. 1 Dose Interim No. 1 Route No. 1 Intervention No. 2 Dose Interim No. 2 Route No. 2
1 vehicle 24 hours Oral None None None
2 cisplatin 6 mg/kg 6 days IP None None None
3 OSU-HDAC42 25 mg/kg 24 hours Oral None None None
4 OSU-HDAC42 50 mg/kg 48 hours Oral None None None
5 SAHA 50 mg/kg 24 hours Oral None None None
6 OSU-HDAC42 25 mg/kg 24 hours Oral Cisplatin 6 mg/kg 6 days IP
7 OSU-HDAC42 50 mg/kg 48 hours Oral Cisplatin 6 mg/kg 6 days IP
8 SAHA 50 mg/kg 24 hours Oral Cisplatin 6 mg/kg 6 days IP
Figure W1. Forty-eight–hour cisplatin dose-response curves for
OVCAR10, CP70, and A2780 cell lines, with respective IC50 values
of 53.1, 42.6, and 3.2 μM. Means ± SE.
Table W2. Comparison of IC50 Values of OSU-HDAC42 and SAHA for Three Different Ovarian
Cancer Cell Lines.
Cell Line OSU-HDAC42 IC50 (μM) SAHA IC50 (μM) Significant at P < .05
A2780 0.39 ± 0.05 0.71 ± 0.07 Yes
Hey 1.40 ± 0.22 2.25 ± 0.5 Yes
HeyC2 1.85 ± 0.36 2.27 ± 0.30 No
Figure W2. Quantitative PCR analysis of p53-regulated (p21 and
NOXA) and p53-independent (γ-globin and Apaf1) gene expression
in (A) A2780 (p53-functional) and (B) CP70 (p53-dysfunctional) cells
after a 24-hour treatment with vehicle or 1.0 μM OSU-HDAC42 or
SAHA. Means ± SE. *P < .05, SAHA or OSU-HDAC42 versus un-
treated; **P < .05, SAHA versus OSU-HDAC42.
Figure W3. Forty-eight–hour cisplatin dose-dependent growth in-
hibition of (A) chemosensitive A2780 cells with or without 4 hours
of 0.5 μM (the A2780 IC50 dose) OSU-HDAC42 pretreatment, or (B)
chemoresistant OVCAR10 cells with or without 4-hour pretreat-
ment with 1.0 μM (respective IC50 value) OSU-HDAC42.
Figure W4. (A) Effects of a 4-hour 0.5 μMOSU-HDAC42 pretreatment of chemosensitive A2780 cells on 48-hour cisplatin dose-dependent,
apoptosis-associated PARP cleavage or (B) annexin V–FITC binding to membrane-externalized phosphatidylserine (with PI used to measure
total cell viability). (C) Identical annexin V–FITC assessment of OVCAR10 cells as in (B), except for pretreatment with 1.0 μMOSU-HDAC42.
